Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase-II-Study of Efficacy of OSAG 101 (Theraloc®) for Adolscent Patients With Recurrent High Grade Glioma

NCT00561873 is registered in ClinicalTrials.gov with Oncoscience AG as lead sponsor.

NCT NCT00561873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00561873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase-II-Study of Efficacy of OSAG 101 (Theraloc®) for Adolscent Patients With Recurrent High Grade Glioma
Lead sponsor
Oncoscience AG
Phase
Observational
Overall status
Completed
Start date
June 30, 2004
Completion date
February 28, 2007
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high grade glioma